HKD 6.09
(-1.62%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 3.37 Billion CNY | 11.86% |
2022 | 3.01 Billion CNY | 27.05% |
2021 | 2.37 Billion CNY | 87.4% |
2020 | 1.26 Billion CNY | 0.0% |
2019 | - CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 3.57 Billion CNY | 6.07% |
2023 FY | 3.37 Billion CNY | 11.86% |
2023 Q2 | 3.3 Billion CNY | 9.67% |
2023 Q4 | 3.37 Billion CNY | 1.99% |
2022 Q4 | 3.01 Billion CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -2106.82% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 52.22% |